-
SHANGHAI, September 26, 2021 - Abiochem has cooperated with a leading diabetes company,Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SH) to produce a generic version of Sitagliptin, and gets approved by CDC (Chinese Center for Disease Control and Prevention) recently. This drug is the first domestic generic drug manufactured based on "non-hydrolase" biosynthetic methods, opening up a new chapter in biosynthetic pharmaceuticals.
-
Chongqing, July 21, 2022 – Abiochem today announced the opening of a new production base in Changshou District, Chongqing Province.
-
SHANGHAI, July 29, 2022 – Abiochem announced its selection as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2021. Abiochem was chosen for its innovative R&D ability and industrialization progress in synthetic biology.
-
GUANGDONG, April 19, 2021 – Abiochem has been invited to attend the 30th meeting of the third deputy council held by the Chinese Chemical Society at Zhuhai International Convention & Exhibition Center, Guangdong, on April, 19th, 2021.
-
CHONGQING, June 18, 2021 - Abiochem today announced that it has signed an investment agreement with the government of Chongqing Changshou District to build a new manufacturing site.
-
SHANGHAI, January 24, 2022 – Abiochem today announced a strategic cooperation with Anhui Jinhe Industrial Co., Ltd. (002597.SZ), a major sweeteners manufacturer in China, and jointly promote cooperation on sugar substitute and non-nutritive sweeteners with the help of synthetic biotechnology.



